Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer (Q57424151)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 August 2011

Language	Label	Description	Also known as
English	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer	scientific article published on 25 August 2011

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

0 references

Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

cancer research

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Fotios Loupakis

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Marta Schirripa

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Diana Giannarelli

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Vittorina Zagonel

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Giampaolo Tortora

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Alfredo Falcone

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Chiara Cremolini

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Vanja Vaccaro

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Federica Cuppone

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Francesco Cognetti

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

language of work or name

0 references

publication date

25 August 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

118

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1523-1532

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

EGFR antibodies in colorectal cancer: where do they belong?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Meta-analyses of randomised clinical trials in oncology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Practical methods for incorporating summary time-to-event data into meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Interpreting Measures of Treatment Effect in Cancer Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Confidence intervals for the number needed to treat

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Biomarkers and surrogate end points--the challenge of statistical validation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

7 January 2021

based on heuristic

inferred from DOI database lookup

Introduction to Meta-Analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.26460

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57424151&oldid=2098223397"